124
Views
10
CrossRef citations to date
0
Altmetric
Letters to the Editor

GATA1 is overexpressed in patients with essential thrombocythemia and polycythemia vera but not in patients with primary myelofibrosis or chronic myelogenous leukemia

, , , , , , & show all
Pages 1416-1419 | Received 21 Feb 2008, Accepted 27 Mar 2008, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Jie Wang, Yun Wu, Md Nazim Uddin, Rong Chen & Jian-Ping Hao. (2021) Identification of Potential Key Genes and Regulatory Markers in Essential Thrombocythemia Through Integrated Bioinformatics Analysis and Clinical Validation. Pharmacogenomics and Personalized Medicine 14, pages 767-784.
Read now

Articles from other publishers (9)

Zi Wang, Pan Wang, Jieying Zhang, Han Gong, Xuchao Zhang, Jianhui Song, Ling Nie, Yuanliang Peng, Yanan Li, Hongling Peng, Yajuan Cui, Heng Li, Bin Hu, Jun Mi, Long Liang, Hong Liu, Ji Zhang, Mao Ye, Karina Yazdanbakhsh, Narla Mohandas, Xiuli An, Xu Han & Jing Liu. (2023) The novel GATA1-interacting protein HES6 is an essential transcriptional cofactor for human erythropoiesis. Nucleic Acids Research 51:10, pages 4774-4790.
Crossref
Hebah Ali, Ignazio Puccio, Ayse U. Akarca, Roshanak Bob, Sabine Pomplun, Wai Keong Wong, Rajeev Gupta, Mallika Sekhar, Jonathan Lambert, Hytham Al‐Masri, Harald Stein & Teresa Marafioti. (2020) Megakaryocytes, erythropoietic and granulopoietic cells express CAL2 antibody in myeloproliferative neoplasms carrying CALR gene mutations. International Journal of Experimental Pathology 102:1, pages 45-50.
Crossref
Valentina Fabiola Ilenia Sangiorgio, Anna Nam, Zhengming Chen, Attilio Orazi & Wayne Tam. (2021) GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms. Leukemia Research 100, pages 106495.
Crossref
James Lally, Kristian Boasman, Lilia Brown, Vincenzo Martinelli, Ilaria Cappuccio, Vishaka Sovani, Christian Marinaccio, John D. Crispino, Ciaren Graham & Ciro Rinaldi. (2019) GATA‐1: A potential novel biomarker for the differentiation of essential thrombocythemia and myelofibrosis. Journal of Thrombosis and Haemostasis 17:6, pages 896-900.
Crossref
Naery YangSholhui ParkMin-Sun ChoMiae LeeKi-Sook HongYeung Chul MunChu-Myong SeongHee Jin HuhJungwon Huh. (2018) GATA1 Expression in BCR/ABL1 -negative Myeloproliferative Neoplasms . Annals of Laboratory Medicine 38:4, pages 296.
Crossref
Gunnar Birgegård. (2016) The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia. Current Hematologic Malignancy Reports 11:5, pages 348-355.
Crossref
Maria Åström, Victoria Hahn-Strömberg, Eva Zetterberg, Inger Vedin, Mats Merup & Jan Palmblad. (2015) X-linked thrombocytopenia with thalassemia displays bone marrow reticulin fibrosis and enhanced angiogenesis: Comparisons with primary myelofibrosis. American Journal of Hematology 90:3, pages E44-E48.
Crossref
M. AHLUWALIA, H. DONOVAN, N. SINGH, L. BUTCHER & J.D. ERUSALIMSKY. (2010) Anagrelide represses GATA‐1 and FOG‐1 expression without interfering with thrombopoietin receptor signal transduction. Journal of Thrombosis and Haemostasis 8:10, pages 2252-2261.
Crossref
Manuel Mutschler, Angela S. Magin, Martina Buerge, Roland Roelz, Daniel H. Schanne, Britta Will, Ingo H. Pilz, Anna Rita Migliaccio & Heike L. Pahl. (2009) NF-E2 overexpression delays erythroid maturation and increases erythrocyte production. British Journal of Haematology 146:2, pages 203-217.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.